Get started
Author

Arnab Basu

ORCID: 0000-0002-8678-3880
Observed ORCID: 0000-0002-8678-3880
OpenAlex ID: A5124044614
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma
2026 · Matthew D. Galsky, Alexandra Drakaki, et al. · Future Oncology · 2
PDF
Clinical efficacy of belzutifan in pre-treated renal cell carcinoma: A real world retrospective cohort benchmarked to LITESPARK-005.
2026 · Mousab Al Abbas, Muhammad Ali Khan, et al. · Journal of Clinical Oncology · 2
PDF
26 Outcomes of Systemic Therapy in Metastatic Translocation Renal Cell Carcinoma (tRCC): A Mayo Clinic Retrospective Study
2026 · Oluwatayo Adeoye, Abiola Bolarinwa, et al. · The Oncologist
PDF
A comparative analysis of frontier large language model (LLM) performance on standardized knowledge assessments and real world scenarios in genitourinary (GU) malignancies.
2026 · Sameer S. Deshmukh, Aaqid Syed, et al. · Journal of Clinical Oncology
OncoSphere AI: An agentic AI multidisciplinary clinical workflow support tool.
2026 · Aakash Desai, Ellen McNeeley, et al. · Journal of Clinical Oncology
Patient experience and quality of life in a decentralized cancer care model for advanced prostate cancer.
2026 · Roxana Stefania Dronca, Trevanne Rose Matthews Hew, et al. · Journal of Clinical Oncology
TROPION-Urothelial03: A phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab vedotin (EV) + pembrolizumab.
2026 · Matthew D. Galsky, Alexandra Drakaki, et al. · Journal of Clinical Oncology
Prognostic value of circulating tumor DNA (ctDNA) for recurrence detection across solid tumors: A real-world meta-analysis.
2026 · Scott Kopetz, George Laliotis, et al. · Journal of Clinical Oncology
57 Final Analysis of the TiNivo-2 Phase 3 Trial: Long-term Outcome of Tivozanib (Tivo) in Patients with Metastatic Renal Cell Carcinoma (mRCC)
2026 · Robert Motzer, Bradley McGregor, et al. · The Oncologist
PDF
Differential quality of life (QoL) with novel hormonal therapy (NHT) in metastatic castration-sensitive prostate cancer (mCSPC): A network meta-analysis of randomized clinical trials.
2026 · Muhammad Uzair Sarfraz, Syed Arsalan Ahmed Naqvi, et al. · Journal of Clinical Oncology
Immune checkpoint inhibitor combinations in sarcomatoid metastatic clear cell renal cell carcinoma: A systematic review and meta-analysis.
2026 · Priya Kumar, Zaryab Bin Riaz, et al. · Journal of Clinical Oncology
Impact of HER2 expression and ERBB2 alterations on clinical outcomes in patients treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis.
2026 · Kevin R. Reyes, Li Zhang, et al. · Journal of Clinical Oncology
PDF
Impact of GLP1 receptor agonists on severity of prostate cancer at diagnosis: A propensity score weighted analysis.
2026 · Muhammad Ali Khan, Viraj R. Shah, et al. · Journal of Clinical Oncology
Leveraging large language models (LLM) to guide adjuvant treatment recommendations for renal cell carcinoma (RCC) after nephrectomy.
2026 · Fouad Nahhat, Arshad Mohammed, et al. · Journal of Clinical Oncology
Circulating tumor DNA kinetics as a biomarker of response to enfortumab-pembrolizumab in advanced urothelial carcinoma.
2026 · Muhammad Abdullah Humayun, Japneet Kaur Oberoi, et al. · Journal of Clinical Oncology
PDF
TROPION-Urothelial03: A phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab vedotin (EV) + pembrolizumab (pembro).
2026 · Matthew D. Galsky, Alexandra Drakaki, et al. · Journal of Clinical Oncology
PDF
Utilization of bone modifying agents in metastatic hormone resistant prostate cancer: A retrospective study of real world patients.
2026 · Yashveer Chohan, Naif A. Ganadily, et al. · Journal of Clinical Oncology
The evolving role of adjuvant immune checkpoint inhibitors in urothelial carcinoma
2026 · Adanma Ayanambakkam, Arnab Basu · Translational Andrology and Urology
Works count: 18
Citation count: 3
H-index: 1
I10-index:
Year
Topic
Type